Amgen Business Development at a Glance

Last Modified Date: February 6, 2018

The acquisition of Onyx Pharmaceuticals in 2013 for their market ready oncology asset Kyprolis was a game changing move for Amgen. Since 2015, buoyed by cheery sales prospects, Amgen has made an increasing number of deals. While the majority of Amgen's acquisition and partnering ventures are in Hematology/Oncology, they have also made exploratory forays into the cardiovascular, immunology, and neuroscience fields.

Amgen Stock

Amgen Inc.
Company Type: Large Pharma
Region: United States, Worldwide
Cash Position: USD 41 678M
Therapeutic Focus: Bone Health, Cardiovascular, Hematology/Oncology, Inflammation, Neuroscience


Deal Activity

Amgen Data

Figure 1. Amgen Inc. In-Licensing Deals and Acquisitions, 2013 through Present (February 2018)

Recent Deal Highlights:

FULL ACQUISITION OF KIRIN-AMGEN JOINT VENTURE FROM KIRIN HOLDINGS

Total Size: USD 810M | Upfront: USD 780M | Therapeutic Area: Hematology/Oncology, Inflammation | Date: October 2017

PRESS | SEC

COLLABORATION WITH CYTOMX THERAPEUTICS FOR PROBODY™ T-CELL ENGAGING BISPECIFIC ANTIBODIES

Total Size: USD 1 445M | Upfront: USD 40M | Therapeutic Area: Hematology/Oncology | Date: October 2017

PRESS

PARTNERING WITH LIGAND PHARMACEUTICALS FOR CAPTISOL TECHNOLOGY

Therapeutic Area: Hematology/Oncology | Date: July 2017

PRESS

R&D PIPELINE

Amgen Pipeline

Figure 2. Amgen Inc. R&D Pipeline at Present (February 2018)

Products from Recent Deals:

ADVAXIS PARTNERED ADXS-NEO ASSET

Disease Area: Hematology/Oncology | Status: Solid Tumors Phase I

ACQUIRED ONYX PHARMACEUTICALS SELECTIVE PROTEASOME INHIBITOR

Disease Area: Hematology/Oncology | Status: R/R Multiple Myeloma Phase III | R/R Peripheral T Cell Lymphoma Phase II | Smouldering Multiple Myeloma Phase II | R/R Mantle Cell Lymphoma Phase II | Neuroendocrine Cancer Phase II | Highly Sensitized Kidney Transplants Phase I | R/R T Cell Lymphoma Phase I | R/R Pediatric Solid Tumors Phase I | Acute Lymphoblastic Leukemia/Lymphoma Phase I

ACQUIRED MICROMETS BISPECIFIC T CELL ENGAGER ANTIBODIES

Disease Area: Hematology/Oncology | Status: R/R B-Cell Non-Hodgkin Lymphoma Phase III | R/R Indolent Non-Hodgkin Lymphoma Phase II | R/R B-Cell Acute Lymphoblastic Leukemia with Pembrolizumab Phase II | Richter Transformation in Hematopoietic/Lymphoid Cancer Phase II | High Risk Diffuse Large B-Cell Lymphoma Phase II

BUSINESS DEVELOPMENT TEAM


Business profiles tailored to your asset.